Second-line treatment for renal cell cancer

British Journal of Cancer

Volumn 106, Issue 4, 2012, Pages 617-618

  Di Lorenzo, G ^a   De Placido, S ^a   Buonerba, C ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; BEVACIZUMAB; DOVITINIB; EVEROLIMUS; INTERFERON; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PAZOPANIB; PLACEBO; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TREBANANIB;

CARDIOTOXICITY; COST EFFECTIVENESS ANALYSIS; DRUG BINDING; DRUG MECHANISM; DRUG POTENTIATION; EDITORIAL; ENDOCRINE DISEASE; HUMAN; KIDNEY CARCINOMA; METASTATIC RENAL CELL CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SKIN TOXICITY;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DRUG ADMINISTRATION SCHEDULE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; PROGNOSIS; PYRIMIDINES; PYRROLES; RETREATMENT; SULFONAMIDES;

EID: 84856878938     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.611     Document Type: Editorial

References (14)

1. Benedict A, Figlin RA, Sandström P, Harmenberg U, Ullén A, Charbonneau C, Sandin R, Remák E, Hariharan S, Négrier S (2011) Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma. BJU Int. 108(5): 665-672
2. Bracarda S, Hutson TE, Porta C, Figlin RA, Calvo V, Grünwald V, Ravaud A, Motzer R, Kim D, Anak O, Panneerselvam A, Escudier B, (2011) Everolimus in metastatic renal cell carcinoma patients intolerant of previous VEGFr-TKI therapy: A RECORD-1 subgroup analysis. Br J Cancer (in issue)
3. Busch J, Seidel C, Kempkensteffen C, Johannsen M, Wolff I, Hinz S, Magheli A, Miller K, Grünwald V, Weikert S (2011) Sequence therapy in patients with metastatic renal cell carcinoma: Comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors. Eur Urol 60: 1163-1170
4. Di Lorenzo G, Buonerba C, Federico P, Rescigno P, Milella M, Ortega C, Aieta M, D'Aniello C, Longo N, Felici A, Ruggeri EM, Palmieri G, Imbimbo C, Aglietta M, De Placido S, Mirone V (2010) Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma. Eur Urol 58(6): 906-911
5. Di Lorenzo G, Cartenì G, Autorino R, Bruni G, Tudini M, Rizzo M, Aieta M, Gonnella A, Rescigno P, Perdonà S, Giannarini G, Pignata S, Longo N, Palmieri G, Imbimbo C, De Laurentiis M, Mirone V, Ficorella C, De Placido S (2009) Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. J Clin Oncol 27(27): 4469-4474
6. Di Lorenzo G, Porta C, Bellmunt J, Sternberg C, Kirkali Z, Staehler M, Joniau S, Montorsi F, Buonerba C (2011) Toxicities of targeted therapy and their management in kidney cancer. Eur Urol 59: 526-540
7. Gore ME, Larkin JM (2011) Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies. Br J Cancer 104(3): 399-406
8. Grünwald V, Seidel C, Fenner M, Ganser A, Busch J, Weikert S. (2011) Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies. Br J Cancer 105(11): 1635-1639
9. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Kay A, Ravaud A (2010) Phase 3 trial of everolimus for metastatic renal cell carcinoma: Final results and analysis of prognostic factors. Cancer 116(18): 4256-4265
10. Powles T, Chowdhury S, Jones R, Mantle M, Nathan P, Bex A, Lim L, Hutson T (2011) Sunitinib and other targeted therapies for renal cell carcinoma. Br J Cancer 104(5): 741-745
11. Rini BI. (2010) New strategies in kidney cancer: Therapeutic advances through understanding the molecular basis of response and resistance. Clin Cancer Res 16(5): 1348-1354
12. Ravasio R, Ortega C, Sabbatini R, Porta C. (2011) Bevacizumab plus interferon-a versus sunitinib for first-line treatment of renal cell carcinoma in Italy: A cost-minimization analysis. Clin Drug Investig 31(7): 507-517
13. Rini BI, Escudier B, Tomczak P (2011) Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial. Lancet 378(9807): 1931-1939. (e-pub ahead of print 3 Nov 2011)
14. Thompson Coon JS, Liu Z, Hoyle M, Hoyle M, Rogers G, Green C, Moxham T, Welch K, Stein K (2009) Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: A systematic review and indirect comparison of clinical effectiveness. Br J Cancer 101: 238-243